Influence of mRNA Covid-19 vaccine dosing interval on the risk of myocarditis
Stéphane Le Vu, Marion Bertrand, Laura Semenzato, Marie-Joëlle Jabagi, Jérémie Botton, Jérôme Drouin, Alain Weill, Rosemary Dray‐Spira, Mahmoud Zureik
Abstract
Myocarditis is the most salient serious adverse event following messenger RNA-based Covid-19 vaccines. The highest risk is observed after the second dose compared to the first, whereas the level of risk associated with more distant booster doses seems to lie in between. We aimed to assess the relation between dosing interval and the risk of myocarditis, for both the two-dose primary series and the third dose (first booster). This matched case-control study included 7911 cases of myocarditis aged 12 or more in a period where approximately 130 million vaccine doses were administered. Here we show that longer intervals between each consecutive dose, including booster, may decrease the occurrence of vaccine-associated myocarditis by up to a factor of 4, especially under age 50. These results suggest that a minimum 6-month interval might be required when scheduling additional booster vaccination. Dosing interval has been suggested as a modifier in the risk of myocarditis associated with Covid-19 mRNA vaccination. Here, the authors show that longer intervals between each consecutive dose, including booster, may decrease the occurrence of myocarditis, especially under age 50.